Advanced search
Publication Cover
Expert Opinion on Drug Safety Volume 21, 2022 - Issue 8
Submit an article Journal homepage
2,790
Views
1
CrossRef citations to date
0
Altmetric
Editorial

Venous thromboembolism risk with Janus kinase inhibitors: Is it a class wide effect?

Ameen Jubbera University Hospitals of Leicester NHS Trust, Infirmary Square, Leicester, UKCorrespondence[email protected]
View further author information
,
Jonathan Woodwardb Royal Free London NHS Foundation Trust, London, UKView further author information
,
Hasan Tahirc Division of Medicine, University College London, London, UKORCID Iconhttps://orcid.org/0000-0002-2148-736XView further author information
ORCID Icon &
Arumugam Moorthyd College of Life Sciences, University of Leicester, Leicester, UKView further author information
Pages 1005-1007 | Received 02 Mar 2022, Accepted 07 Jul 2022, Published online: 13 Jul 2022

References

  • Ytterberg SR, Bhatt DL, and Mikuls TR, et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med. 2022; 386(4): 316–326.
  • Mease P, Charles-Schoeman C, Cohen S, et al. Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data. Ann Rheum Dis. 2020;79(11):1400–1413.
  • Kremer JM, Bingham CO 3rd, and Cappelli LC, et al. Postapproval comparative safety study of tofacitinib and biological disease-modifying antirheumatic drugs: 5-year results from a United States–based rheumatoid arthritis registry. ACR Open Rheumatol. 2021; 3(3): 173–184.
  • Taylor PC, Weinblatt ME, and Burmester GR, et al. Cardiovascular safety during treatment with baricitinib in rheumatoid arthritis. Arthritis Rheumatol. 2019; 71(7): 1042–1055.
  • Kim SC, Schneeweiss S, Liu J, et al. Risk of venous thromboembolism in patients with rheumatoid arthritis. Arthritis Care Res. 2013;65:1600–1607.
  • Cohen SB, van Vollenhoven RF, Winthrop KL, et al. Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme [published online ahead of print, 2020 Oct 28] [published correction appears in Ann Rheum Dis. 2021;80(5):e83]. Ann Rheum Dis. 2020;80(3):304–311.
  • Choy E, Mcinnes I, Cush J, et al. Incidence and risk of venous thromboembolic events among patients with rheumatoid arthritis enrolled in the upadacitinib clinical trial program. Ann Rheum Dis. 2020;79:317–318.
  • Winthrop KL, Tanaka Y, Takeuchi T, et al. Integrated safety analysis of filgotinib in patients with moderately to severely active rheumatoid arthritis receiving treatment over a median of 1.6 years. Ann Rheum Dis. 2022;81(2):184–192.
  • Takeuchi T, Tanaka Y, Tanaka S, et al. Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: final results (32 months of mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan. Rheumatol Ther. 2021;8(1):425–442.
  • Scott IC, Hider SL, Scott DL. Thromboembolism with Janus Kinase (JAK) inhibitors for rheumatoid arthritis: how real is the risk? Drug Saf. 2018;41(7):645–653.
  • Yates M, Mootoo A, and Adas M, et al. Venous thromboembolism risk with JAK inhibitors: a meta-analysis. Arthritis Rheumatol. 2021; 73(5): 779–788.
  • Cohen SB. JAK inhibitors and VTE risk: how concerned should we be? Nat Rev Rheumatol. 2021;17(3):133–134.
  • Mori S, Ogata F, Tsunoda R. Risk of venous thromboembolism associated with Janus kinase inhibitors for rheumatoid arthritis: case presentation and literature review. Clin Rheumatol. 2021;40(11):4457–4471.
  • Clarke B, Yates M, and Adas M, et al. The safety of JAK-1 inhibitors. Rheumatology. 2021; 60(Supplement_2): ii24–30.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.